Regulator or Enabler? Germany’s Paul Ehrlich Institute and the Pfizer-BioNTech Vaccine
Given the tremendous economic significance of BioNTech’s success for the German economy, one can wonder in general about the wisdom of having the German regulator serve as the regulator responsible for releasing batches to all EU member states. The potential conflict of interest is obvious. BioNTech’s mercurial rise was, for instance, the very motor of Germany’s return to growth in 2021, to say nothing of the roughly 30 percent of its profits that the company pays in corporate tax.
Regulator or Enabler? Germany’s Paul Ehrlich Institute and the Pfizer-BioNTech Vaccine Read More »